本发明的新颖的酚衍生物是有效的特异性，足够稳定的5- Lipoxygenenase抑制剂和特别是在用于Arzneimittelzübereitungsformen在与白三烯有关作为调停的病理状况的治疗中，可以使用。 它们对应于通式其中A和B是相同的或-CH = CH-或反式-CH =不同的，并且如所定义的各-C ^ C-，顺CH-，R 1是氢或任选取代的烷基，环烷基 - ，或苯基，R2和R3定义的基团之一，优选氢，表示，R 4是氢，烷基或酰基，R 6代表羧基或其功能衍生物，或为游离，醚化或酯化的羟基基团和R 6是一个限定 基，优选氢或甲氧基的装置。 根据本发明的制备式I特别是通过建筑脂族链的，从适当的乙炔化合物或通过使用维蒂希Reamionen起始化合物的。 在R5的剩余部分可以是，实施例，可以随后被转化为其它所需的Carboxygruppenderivate。 特别地，通过催化氢化，A和B可以定义的范围内变化。

The novel phenol derivatives of the invention are specifically effective, sufficiently stable 5-Lipoxygenenase inhibitors and in particular in drug composition forms for the therapy of pathological states in which leukotrienes are involved as mediators, can be used. They correspond to the general formula wherein A and B -C = C-, cis-CH = is the same or different and each CH- or trans-CH = CH-, R, is hydrogen or an optionally substituted as defined alkyl, cycloalkyl or phenyl radical, R ₂ and R _{3 is} a defined radicals, preferably hydrogen; R ₄ is hydrogen, alkyl or acyl, R ₅ represents a carboxyl group or a functional derivative thereof, or for a free, etherified or esterified hydroxy group and R ₆ one of the groups defined, preferably hydrogen or methoxy, means. The inventive preparation of the compounds of formula I is effected in particular by building the aliphatic chain, starting from the appropriate acetylene compounds or by means of Wittig reactions. The radical R ₅ can then be converted to z. B. in other desired Carboxygruppenderivate. In particular, by catalytic hydrogenation A and B can be varied within the definition.